Mayo Clinic Analysis of 256,492 Adults With Prediabetes Ties GLP-1 Drugs to 31% Lower Diabetes Risk Than Metformin
Among 256,492 adults with prediabetes and obesity in the TriNetX health-record network from 2010 to 2023, those prescribed a GLP-1 drug had a 31% lower risk of developing type 2 diabetes, 41% lower risk of death, and fewer heart attacks, strokes, and heart failure cases than matched patients on metformin over about three years, Mayo Clinic researchers reported in an abstract for the AHA's Scientific Sessions, November 6-9. The study is observational and not yet peer-reviewed, and the lead author called metformin still a first-line choice.